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Abstract
Biomarkers for early detection of cancer have great clinical diagnostic potential. Numerous reports
have documented the generation of humoral immune responses that are triggered in response to
changes in protein expression patterns in tumor tissues and these biomarkers are referred to as
tumor associated antigens (TAAs). Using a high-throughput technology, we previously identified
65 proteins as diagnostically useful TAAs by profiling the humoral immune responses in ovarian
cancer (OVCA) patients. Here we determined the expression status of some of those TAAs in
tissues from OVCA patients. The protein expression patterns of 4 of those 65 antigens, namely
NASP, RCAS1, Nijmegen breakage syndrome1 (NBS1) and eIF5A, along with p53 and Her2
(known molecular prognosticators) and two proteins that interact with NBS1, MRE11 and
RAD50, were assessed by immunohistochemistry (IHC). NASP and RCAS1 proteins were more
frequently expressed in ovarian cancer tissues than with normal ovarian tissue and serous
cystadenomas and MRE11 was less frequently expressed. When evaluated simultaneously, only
NASP and MRE11 remained statistically significant with sensitivity of 66% and specificity of
89%. None of these proteins’ expression levels were prognostic for survival. Together, our results
indicate that occurrence of humoral immune responses against some of these TAAs in OVCA
patients is triggered by antigen protein overexpression.
© 2009/2010 – IOS Press and the authors. All rights reserved
*Corresponding author. Tel.: +1 313 578 4340; Fax: +1 313 832 7294; tainskym@karmanos.org.
1Both should be considered first authors.
NIH Public Access
Author Manuscript
Cancer Biomark. Author manuscript; available in PMC 2012 May 03.
Published in final edited form as:














Ovarian cancer; phage display; tissue biomarker; humoral immune response; tissue microarray
1. Introduction
Epithelial ovarian cancer is the eighth most common malignancy in the United States, with
nearly 15,000 deaths annually [20]. Screening for ovarian cancer has been based on
strategies using serum tumor markers or ultrasound imaging of the ovaries. A recent report
from Menon et al. indicates that specificity of multimodal screening (annual CA125
screening with transvaginal ultrasound (TVS) as a second-line test) is higher than annual
screening with TVS alone for all primary epithelial ovarian and tubal cancers [28].
However, CA125 is elevated in only about 50% of patients with clinically detectable early
stage OVCA [26]. Therefore, there is a need for new technologies to identify a panel of
biomarkers that can be used in a non-invasive screening test that has both high sensitivity
and high specificity in the heterogeneous population of ovarian cancer patients.
Proteomic technologies have proved useful in the field of discovery of tumor tissue
biomarkers. Candidate tissue biomarkers of ovarian tumors are often derived from studies of
overexpression of mRNAs that were previously found to be up-regulated in ovarian cancer
by analyses of gene expression [18]. Many tumor antigens have been reported to be
overexpressed (at protein level) in OVCA; these include cell cycle proteins [27], cancer
testis antigens like MAGE- A4 and NY-ESO-1 [49]. TAAs can also be identified in studies
of proteins that are shed from cancer cells into the circulation [25] and can form blocking
factors with the antibodies that may help tumors escape immune surveillance [45].
It has been reported that numerous intracellular proteins can elicit humoral immune
responses in different cancer patients [44] as a result of aberrant expression of antigen
biomarkers [7], alternative splicing of pre-messenger RNAs [47], point mutations [48] and
over-expression [10] or post-translation alterations of the expressed antigens such as
changes in glycosylation [15], phosphorylation [12]. Proteomic approaches that are based on
the idea of using serum antibody responses to different autoantigens are multifaceted and
may provide more reliable serum markers for diagnosis of cancer [32,38].
In searching for a more robust method for the early detection of OVCA, we chose to identify
large numbers of potential diagnostic antibodies in serum and developed a high-throughput
strategy to clone antigen biomarkers. We refer to this approach as “epitomics” [13]. Because
antibodies to any single antigen tend to detect only a small fraction of individuals with
cancer, we recognized the necessity to screen a large panel of potential antigen markers.
Therefore, we used a differential biopanning technique to screen T7 phage display cDNA
libraries to isolate cDNAs coding for epitopes binding to antibodies present specifically in
the sera of patients with early or late stage OVCA but not binding with antibodies in the sera
of healthy women. Protein microarray-based immunoassays of 480 phage clones obtained
by differential biopanning of a T7 phage OVCA cDNA library with sera obtained from
cancer patients, patients with benign gynecological diseases and healthy females resulted in
the identification of 65 antigens [6]. The statistical validation of these 65 biomarkers was
then conducted on a different array platform using independent serum samples. The
objective of this study was to determine the association of the expression patterns of a subset
of those 65 OVCA antigens that we identified through epitomics with 1) the generation of
humoral immune responses in OVCA patients and, 2) the clinical characteristics of OVCA
in patients’ tumor tissues. We evaluated the protein expression levels of a panel of 4
antigens namely, NASP, RCAS1, NBS1, eIF5A, along with 2 known prognostic factors p53
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and Her2 and two other proteins MRE11 and RAD50 that interact with NBS1 (the MRN
complex), by immunohistochemical staining of tumor specimens of paraffin-embedded
tissues and tissue microarrays obtained from women who had epithelial ovarian cancer at a
variety of stages and histotypes. We found that some epitomics antigens were overexpressed
in OVCA relative to normal or benign ovarian tissues thus indicating that overexpression of
those antigens resulted in their immunogenicity. Over-expression of NASP effectively
discriminated OVCA from healthy or benign tissues. None of the biomarkers distinguished
healthy tissues from benign or non-serous tumors from serous tumors; however, RCAS1 did
distinguish early stage from late stage OVCA. None of the markers provided prognostic
information relevant to overall survival.
2. Materials and methods
2.1. Patients
This study was open to women newly diagnosed with OVCA or who were within five years
of initial diagnosis or a recurrence occurring between 1997 and 2005 (Cohort I). We used
formalin fixed, paraffin embedded tissue sections (FFPE) from 126 women who underwent
primary surgery and received no chemotherapy or radiation therapy prior to their surgery
(Median age = 57, IQR = 49–67). The normal control group included 20 patients who had
undergone a hysterectomy and bilateral salpingo-oophorectomy due to uterine leiomyoma
(Median age = 49, IQR = 44–60). Another control group included 20 women who had
benign ovarian serous cystadenoma (Median age = 52, IQR = 42–66) (Table 1A). Blocks
were obtained from the Detroit Medical Center/Barbara Ann Karmanos Cancer Institute
Pathology Core Facility and the Gynecologic Oncology Group Tissue Bank (GOG). H&E
stained slides for all cases and controls were reviewed for confirmation of diagnosis and
histology by the study pathologist (RA-F); only cases with serous, mucinous, endometrioid,
or clear cell histology were utilized. An alternative classification strategy developed by Shih
and Kurman was also employed (Figs 5–6) [40]. In this model all low-grade serous,
mucinous, endometrioid, or clear cell carcinoma surface epithelial ovarian tumors are
designated as Type I; high-grade serous carcinoma is designated as Type II so as to
distinguish indolent, low-grade ovarian neoplasms from high-grade lesions that behave far
more aggressively, yet appear to have no precursor lesion.
Because of missing data on vital status and follow-up, we were unable to assess the
predictive utility of the markers on survival in this cohort. We therefore evaluated survival
using a tissue microarray constructed by the Karmanos Cancer Institute Pathology Core
Facility (Cohort II) in a cohort comprised of patients who were diagnosed with epithelial
ovarian carcinoma between 1985 and 2004 (n = 200) (Table 1B). Demographic data and
information on surgical treatment was obtained from a retrospective review of medical
records. Survival data were retrieved using the institutional Clinical Information System and
the Metropolitan Detroit Cancer Surveillance System Database (MDCSS), a participant in
the National SEER Registry. Surgical staging was determined using the criteria
recommended by International Federation of Gynecology and Obstetrics (FIGO). Histologic
type and grade were determined using previously described World Health Organization
criteria. Tissue microarrays were prepared from FFPE blocks using a manual tissue arrayer
(MTA-1, Beecher Instruments, Sun Prairie WI). A single block was selected per case and
from each block, three 1.5 mm diameter cores were obtained [2,34].
All protocols were approved by the Wayne State University Human Investigation
Committee. A waiver of consent was obtained for the retrospective review of archived
material.
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We also evaluated an additional cohort using independent tissue microarray provided by the
Tissue Array Research Program (TARP) of the National Cancer Institute, National Institutes
of Health, Bethesda, MD. The NCI TARP3 array consisted of 500 anonymized samples
representing a variety of malignant and normal tissues: Healthy (n = 50), Brain Tumor (n =
25), Breast Adenocarcinoma (n = 75), Colonic Adenocarcinoma (n = 75), Lung Cancer (n =
75), Lymphoma (n = 50), Melanoma (n = 25), Ovarian Adenocarcinoma (n = 50), Prostatic
Adenocarcinoma (n = 75). The FFPE tissue used to construct this array was provided by the
Cooperative Human Tissue Network (CHTN).
2.2. Immunohistochemistry
The protein expression levels of NASP, RCAS1, NBS1, MRE11, RAD50, eIF5A, p53 and
Her2 were measured by immunohistochemical staining of 4 μm sections or tissue
microarray (TMA) cores from FF-PE tissue. Staining was either carried out manually or by
using the Ventana automated instrument, BenchMark- XT following manufacturer’s
instructions (Ventana Medical Systems, Inc., 1910 Innovation Park Drive, Tucson, AZ.
85737).
Manual immunostaining using primary antibodies for Her2, NASP, NBS1 and
RCAS1—Each section was deparaffinized and subjected to immunohistochemical staining
with standard streptavidinbiotin-peroxidase techniques, with diaminobenzidine as the
chromogen.
Automated immunostaining using primary antibodies for eIF5A, p53, MRE11
and RAD50—Sections were deparaffinized with a solution of EZ-Prep (Ventana
#950-101), rinsed with reaction buffer (Ventana #950-300) and treated with inhibitor
solution (Ventana DAB detection kit #760-2021) to decrease the endogenous peroxidase
activity.
Additional details for both manual and automated processes are listed in Table 2.
Two pathologists (RA-F and HA) who were blinded to the demographic and clinical
information about the participants evaluated the tissue sections and cores under a light
microscope. For evaluating the expression of the parameters, the areas of highest staining
density were identified. For the expression of Her2 strong and complete membranous
expression in greater than 5% of the cells was defined as positive staining. Cytoplasmic
expression of eIF5A and RCAS1 was considered positive when expressed in more than 5%
of the tumor cells. Nuclear expression was estimated to evaluate the expression of NASP,
NBS1, RAD50, MRE11 and p53 and considered positive when expressed in more than 5%
of tumor cells after counting at least 1000 cells. If the percentage of stained cells was less
than or equal to five percent, the case was considered negative, and if it exceeded five
percent, the case was considered positive (Table 3(A–D)).
Tissue microarray—The TARP3 TMA was read by SMH. p53 was scored as negative
(≤5% tumor cells), or positive (>5% tumor cells). Her2 was scored as 1, 2, or 3 (per standard
Her2 protocol), eIF5A, NASP, and RCAS1 were scored as negative (no staining seen), weak
(score 1), intermediate/moderate (score 2), or strong (score 3). For technical reasons we
were not able to analyze protein expression of NBS, MRE11 and RAD50 on the TARP3
TMA.
2.3. Statistical analyses
Association between biomarkers was assessed with two-sided Fisher’s exact tests.
Association of age with biomarker expression was evaluated using Kruskal-Wallis tests.
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Discriminatory ability of the antigen biomarkers was assessed with logistic regression.
Survival times were computed from the date of diagnosis to the date of death or last follow-
up. Cox regression models, controlling for age and stage were used to evaluate prognostic
value of the markers for overall survival. Bootstrapping with 1000 replications of each
model was used for internal validation. Significance levels are adjusted for multiple
comparisons using Holm’s method [17].
2.4. Determination of mRNA level of biomarkers by quantitative real time pcr (Q-RT-PCR)
Total RNA was isolated from the surgical tumor specimens obtained from patients with
malignant serous ovarian carcinoma using RNeasy kit (Qiagen Inc., Valencia, CA, USA).
Total RNA (2 μg) was reversed transcribed into cDNA using Superscript II (Life
Technologies, Gaithersburg, MD, USA). The quantitation of mRNA using Q-RT-PCR was
performed following the methods as described previously [23].
3. Results
Humoral immunity resulting in the development of autoantibodies directed against TAAs is
being employed as a potential diagnostic tool for early detection of cancer. Studies have
shown that circulating antibodies can be detected long before there are clinical
manifestations of cancer [24]. The humoral immune responses in cancer patients are related
to overexpression of proteins i.e. Her2 [10], aberrant expression of mutated proteins or
proteins with various post-translational modification in tumor cells [11,19,39]. In our
previous study, which was mainly directed at the discovery of tumor biomarkers in serum,
we profiled humoral immune responses elicited in OVCA patients [6]. The expression of a
small subset of those previously identified 65 biomarkers was analyzed in this study to
better understand the mechanism by which humoral immune responses are generated in
OVCA patients and to determine whether TAAs have value as tissue biomarkers. IHC was
performed at the protein level for 4 of these biomarkers to determine if their
immunogenicity was due to overexpression.
3.1. Immunohistochemical staining for tissue biomarkers
Analyses were restricted to cases with serous, mucinous, endometroid, or clear cell histology
(Table 1B). Among the 65 biomarkers identified by serum immunoscreening [6], we were
able to acquire antibodies for expression studies of 4 biomarkers, NASP [1, 36], NBS1,
RCAS1, and eIF5A. We also analyzed 2 known biomarkers of OVCA, p53 and Her2 (Table
2). Although MRE11 and RAD50 were not members of the group of 65 biomarkers, we
assessed their expression because these proteins physically interact in cells with NBS1 at
sites of DNA double strand breaks after the formation of a ternary complex. Eventually the
MRE11/RAD50/NBS1 (MRN) complex gets recruited to the site of DNA double-strand
breaks for DNA repair [21].
Overexpression of NASP protein was observed in 46% of patients with OVCA, in 5% of
patients with serous cystadenoma, and in 5% normal ovaries ((Fig. 1A, 3A) and Table 3(A–
B)). Overexpression of RCAS1 protein was observed in 81% of late stage OVCA patients,
in 50% of patients with serous cystadenoma, and in 20% of women with normal ovaries
((Fig. 1B, 3B) and Table 3(B–C)). Both NASP and RCAS1 provided good utility in
discriminating cancer from healthy as described later. None of the other markers such as,
eIF5A (Fig. 1C, 3C), NBS1 (Fig. 1D, 3D), MRE11 (Fig. 2A, 4A) and RAD50 (Fig. 2B, 4B)
showed markedly higher expression in all OVCA patients compared to women with serous
cystadenoma and those with normal ovaries (Table 3A, 3B). Although expression of MRE11
and RAD50 proteins was lower in OVCA patients than in the control groups (healthy ovary
and serous cystadenoma), these markers did not adequately discriminate between control
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groups and cancer because the expression pattern of these antigens did not differ
significantly between control groups and cancer. Among the known prognostic biomarkers,
overexpression of Her2 protein was observed in 29% of all OVCA patients, in 30% of
serous cystadenoma patients, and in 5% of women with normal ovaries ((Fig. 2C, 4C) and
Table 3 (A-B)). Overexpression of p53 protein was observed in 45% of all OVCA patients,
in none of serous cystadenoma patients, and in none of the normal ovaries ((Fig. 2D, 4D)
and Table 3(A–B)). An alternative classification strategy was employed in which all low-
grade serous, mucinous, endometrioid, or clear cell carcinoma surface epithelial ovarian
tumors were designated as Type I and high-grade serous carcinoma was designated as Type
II [40]. All the markers except NBS1 retained their significance when tumors were classified
as Type I, Type II rather than serous, non-serous (Figs 5–6).
Seventy six out of two hundred OVCA patients used for the immunoscreeningon protein
microarrays for the identification of autoantigens were also used for IHC analysis to
evaluate the expression of those antigens in the tumor specimens obtained from the same
OVCA patients. However, we did not see a relationship between dye ratio (microarray
analysis) and intensity x % cells staining (IHC analysis) for the OVCA patients used in both
the analyses.
3.2. Diagnostic value of biomarkers
When the markers were evaluated one at a time for their ability to discriminate between
healthy ovaries and serous cystadenoma from ovarian cancer, we found that NASP (p <
0.001) and RCAS1 (p = 0.01) were significantly more likely to be positive in tissues from
women with OVCA (Table 3A) and MRE11 (p = 0.01) was less likely to be positive. p53
could not be evaluated because none of the healthy ovaries or those with benign tumors
expressed p53. With the exception of p53 (p = 0.02), (data not shown) there were no
statistically significant differences in age between women who expressed the antigen marker
and those who did not (all p > 0.50).
When the markers were evaluated simultaneously, NASP (p < 0.001) and MRE11 (p =
0.004) retained their significance, but RCAS1 did not (p = 0.22), which is probably due to
the association between RCAS1 and NASP (p < 0.002), uncorrected for multiple
comparisons). Using a 2 marker model, the probability of OV-CA is 57% for women who
are negative for NASP and positive for MRE11; the probability of OVCA is 99% for women
who are positive for NASP and negative for MRE11. The probability of OVCA is 92% for
women who are negative for both markers and 96% for women who are positive for both
markers. If a positive test is defined as having a predicted probability greater than 90%, this
model has 66% sensitivity and 89% specificity and the area under the ROC curve is 0.78.
When the markers were evaluated further one at a time (Table 3B), we found that only
HER2 expression (p = 0.02) was differentially expressed between healthy ovaries and
benign serous cystadenomas; in the model with all of the markers, none were statistically
significant. NASP (p = 0.02), RCAS1 (p = 0.01) and RAD50 (p = 0.02) were found to be
more common in women with late stage disease than in those with early stage disease in
single marker models and RCAS1 (p = 0.04) remained a significant predictor of late stage
disease when evaluated in a multivariable model with all of the other markers (Table 3C).
NASP (p < 0.001), p53 (p = 0.02), RAD50 (p = 0.006) and NBS1 (p < 0.001) and RCAS1 (p
= 0.04) were more common in with women serous ovarian cancer than in those with non-
serous disease in single marker models, but none were important discriminators in the
multivariable model (Table 3D). The conclusions are the same when women are categorized
as having Type I or Type II disease.
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3.3. Utility of markers against other cancers
Useful markers should not only distinguish healthy and benign ovaries from OVCA
samples, but differentiate between ovarian and other cancers as well. We assessed utility of
p53, NASP, Her2, eIF5A, and RCAS1 on tissue microarrays from samples with other
cancers (see Materials and Methods). The best markers for classification of OVCA against
other cancers were NASP (SN=64%, SP=75%) and p53 (SN=32%, SP=94%). Because one
marker may be not sufficient for a good classifier, we assessed the utility of combination of
p53 and NASP. Comparing OVCA with other cancers, sensitivity and specificity were 66%
and 75% respectively. Because of the enhanced risk of breast and colon cancers along with
OVCA in high-risk BRCA1 and BR-CA2 families, it was important to determine
discriminatory accuracy of the tissue biomarkers for these cancers compared to OVCA [4].
Individually, NASP had the highest accuracy with 64% sensitivity for OVCA and specificity
of 73% and 68% to breast and colon cancer respectively. If individuals are classified as
positive if any of p53, Her2, and NASP are positive, sensitivity to distinguish OVCA from
breast and colon cancer is 81%, while specificity is 58% and 46% to breast and colon cancer
respectively. Overall, NASP and p53 were the best markers at distinguishing OVCA from
other cancers, but neither was adequate.
3.4. Prognostic value for survival
The prognostic value of the markers for survival was assessed using samples from 200
patients in cohort II (Table 1B). Approximately half (104/200) have died and median
follow-up time for those still alive is 44 months. More than 75% of the women in cohort II
expressed NASP, RCAS1, RAD50 or eIF5A (Table 4). Nearly 2/3rd expressed MRE11,
almost half expressed NBS1 or p53 while 12% expressed Her2. When assessed for
prognostic value after adjusting for the known prognostic factors age at diagnosis, stage of
disease and whether the tumor grade was borderline or not, none of the individual markers
nor the combination was significantly associated with survival.
3.5. Correlative study of antigen expression at mRNA level (Q-RT-PCR) and protein level
(IHC)
To examine the relationship between expression at mRNA and protein level, we used fold
change score for Q-RT-PCR data and percentage of cells stained positive for the biomarkers
(NASP, RCAS1, NBS1, MRE11, RAD50, eIF5A, p53 and Her2) as assessed by IHC. NASP
and MRE11 showed positive correlations between expression at mRNA and protein level:
NASP Spearman rho = 0.68 (p = 0.02).
4. Discussion
The humoral immune response plays an important role in self-defense against various
diseases including cancer. Numerous studies have reported the presence of circulating tumor
reactive immunoglobulins (IgGs) in patients diagnosed with melanoma [29], breast [9], and
OVCA [46]. The generation of antibodies directed against intracellular antigens, such as c-
Myc and p53, as a result of tissue destruction has been reported in cancer patients [5]. The
humoral immune response can be induced by inappropriate expression or overexpression of
self-antigens (silent or expressed at low level in normal tissues) [30] besides other
mechanisms as discussed earlier. The occurrence of immunogenicity of self-antigens due to
overexpression is based on the growing evidence that support the presence of self-reactive
T-cells in the T-cell repertoire that are able to recognize endogenous peptides derived from
self-antigen. Studies have shown that only well-expressed self-antigen determinants are
efficient in tolerizing T-cells. However, there are ‘subdominant’ or ‘cryptic’ determinants of
self-antigens that are poorly processed from native molecule and inefficiently presented to T
cells and do not induce such tolerance [8]. But when overexpression of self-antigen occurs
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in cancer, these cryptic determinants are presented to T-cells in context with MHC
molecules in the presence of various co-stimulatory molecules in the tumor
microenvironment and elicit immunological responses [31].
In our previous study, we established a new technology to find TAAs in OVCA patients by
exploiting autoantibody signatures in OVCA patients. We identified 65 protein biomarkers
by profiling humoral immune response in OVCA patients using high-throughputepitomics
technology [6]. In order to determine the mechanism for the generation of immunogenicity
of TAA biomarkers, we analyzed 4 of 65 antigens for which the antibodies were available
for expression at the protein level. Immunohistochemical staining of tissue sections
(obtained from OVCA patients) was performed to detect the expression profiles of NASP,
RCAS1, NBS1, eIF5A (a subset of the 65 antigens), MRE11, RAD50, as well as p53 and
Her2 (known prognostic biomarkers).
The IHC analysis revealed overexpression of NASP in OVCA patients when compared to
serous cystadenoma patients or in normal ovary as shown in Table 3 (AB). NASP is a
histone H1-binding protein and provides efficient transport of histones into the nucleus
during cell division cycle and helps in nucleosome remodeling during DNA replication [37].
As NASP is a cell cycle regulated protein, overexpression of NASP as indicated by our
results may be involved in higher level of mitotic activity and cell proliferation in ovarian
cancer as shown in other studies in Hela cells by Richardson et al. [36]. Oram et al. reported
that testis specific protein Y-encoded (TSPY) gene, a histone binding protein involved in
cell cycle regulation, was shown to potentiate cell proliferation and tumoregenesis in Hela
and NIH3T3 cells [33]. Based on the above facts, a possible functional role of NASP in
tumor progression in OVCA can be envisioned but further experimental investigation is
necessary. On the other hand, RCAS1 showed overexpression only in the late stage serous
OVCA patients when compared to serous cystadenoma patients or in normal ovary (Table 3
(B-C)). RCAS1 is a membrane protein that is released into circulation by ectodomain
shedding and is involved in the induction of apoptotic cell death of lymphocytes thereby
allowing tumor to escape immune surveillance in cancer patients [41]. Previously,
overexpression of RCAS1 in uterine and ovarian carcinomas was reported by Sonoda et al.
[43] and their recent study indicated that a significantly higher concentration of serum
RCAS1 in OVCA patients that suggested that RCAS1 may be involved in tumor progression
in OVCA patients [42]. Thus, our results of overexpression of RCAS1 in OV-CA are in
accordance with other published studies. Disis et al. reported a direct correlation between the
degree of generation of humoral immune response and overexpression of Her2 in breast
cancer patients [14]. Their study showed that the endogenous Her2-specific humoral
immune response was greater in patients with Her2 overexpressing tumors than in patients
who had lower levels of Her2 expression. Our previous study already had reflected the
generation of immune responses against NASP and RCAS1 antigens because these antigens
were identified on protein arrays when interrogated with IgGs from OVCA patients’ sera
[6]. In the current study, NASP, NBS1, RAD50 and RCAS1 as well as p53 were more
commonly expressed in serous ovarian tumor specimens than in non-serous. Overall, this
result indicates that overexpression of these TAAs may be related to the generation of
humoral immune responses in OVCA patients. Interestingly, 76 of the OVCA patients used
for the detection of autoantigens by immunoscreening on protein microarrays were also
tested for protein expression analysis by IHC in the tumor tissue specimens obtained from
the same OVCA patients. However, we did not observe any correlation between serum IgG
level binding to that antigen on microarray analysis and the protein expression level of
tumor antigens in IHC analysis. The observed humoral immune response may not always
correlate with the overexpression of tumor antigens because of a number of reasons. First,
serum antibodies are polyclonal in nature and some patients may have antibodies that are
directed towards the cloned epitope of an antigen, while others may have antibodies
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exhibiting higher affinity for a different epitope other than the cloned one. Therefore, in
these patients humoral immune response against that specific antigen may not be detectable
on protein microarrays despite its over-expression. Second, the excess antigens shed from
tumors can bind to their corresponding antibodies in the circulation thus interfering with the
binding of T-cell receptors to an epitope of tumor antigens for which they are specific.
These blocking factors may cause a lowering of serum IgGs for specific antigen in cancer
patients [45]. Third, reports from different studies suggest that TAAs that are carried to the
lymph nodes and are presented to T-cells by antigen presenting cells can drive clonal
deletion [22] or anergy [3] in different tumor microenvironments of cancer patients.
The difference in levels of protein expression between women with OVCA and controls is
not statistically significant for RCAS1, RAD50, Her2, NBS1, eIF5A and p53 (all p ≥0.30).
The level of MRE11 protein expression is significantly lower (p = −0.004) in OVCA
patients than in controls and the levels of NASP (p < 0.001) is significantly higher. Based on
the relative expression profiles of NBS1, MRE11 and RAD50 in ovarian tumors compared
to serous cystadenomas or normal ovaries, our result may indicate the absence of an intact
DNA double strand breaks repair pathway in OVCA patients. As MRN complex plays an
integral role in cellular response to DNA double strands breaks, decreased MRN levels
could be associated with progression in tumor development through less efficient DSB
repair in combination with impaired checkpoint signaling and an apoptotic defect. As
overexpression for NBS1, MRE11 and RAD50 was not observed in OVCA patients, the
cause for their immunogenicity may be due to presence of mutations in the respective genes
in cancer patients as reported from other studies. A report from Plisiecka-Halasa et al.
indicated presence of NBS1 gene mutation in OVCA patients [35]. Mutations in MRE11
and RAD50 genes in breast cancer or OVCA was reported by Heikkinen et al. [16].
Genomic analysis for somatic mutations within these 3 genes was beyond the scope of the
present study.
The expression of known prognostic markers like p53 and Her2 was also analyzed by IHC.
p53 showed overexpression in OVCA patients compared to ovaries in serous cystadenoma
patients. Although p53 was highly specific in distinguishing between OVCA and control
group, this marker did not have prognostic utility as reported in previous studies. Other
markers individually or in combination were not significant predictors of survival.
We assessed utility of markers to distinguish OVCA from the control non-cancer group
individually, as a panel of markers, to distinguish between early and late stage, as well as
specificity to OVCA against benign conditions and other cancers. Based on these analyses,
NASP was more likely to be positive in all OV-CA, serous, early stage, and late stage
OVCA tissues compared to non-cancer group. Moreover, NASP was more likely to be
positive in serous compared to non-serous OVCA, and in OVCA compared to other cancers.
Overall, this study shows that finding biomarkers with high-throughput epitomic technology
is a promising new way to identify tissue biomarkers for cancer.
An evaluation of the associations between expression of antigens at protein and mRNA level
was also performed in this study. A highly significant correlation between expression at
mRNA and protein level was obtained for NASP (Spearman rho = 0.68 (p = 0.02)). This
result suggests that the expression of NASP may be regulated at the transcriptional level in
these tissues. However, no significant associations were found for the other biomarkers.
Overexpression of 6 out of 8 mR-NAs for these markers namely, NASP, eIF5A, NBS1,
RAD50, Her2, and p53 in ovarian carcinoma compared to normal ovary was found in the
Oncomine database of ovarian Oncomine Gene Expression Signatures.9
9Oncomine database is available at http://www.oncomine.org/ocm/main/main.jsp.
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In conclusion, by profiling humoral immune responses in OVCA patients we identified
diagnostically useful TAAs using a protein microarray-based high-throughput technology.
We demonstrated that overexpression of some of these TAAs at the protein level as assessed
by IHC, may be related to the generation of their immunogenicity that elicited humoral
immune responses in OVCA patients. Although identified for their diagnostic utility, these
TAAs for early detection of OVCA in serum also have diagnostic potential as tissue
biomarkers. This new panel of biomarkers will hold promise as potential tissue biomarkers
that may have better therapeutic utility in a clinical setting of cancer screening and
prevention.
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Immunohistochemical staining for NASP, RCAS1, eIF5A and NBS1 in tissue sections
obtained from a patient with serous high grade carcinoma. IHC was performed to determine
the protein expression level of 4 serological biomarkers (mentioned above) that were
previously identified by profiling humoral immune responses in OVCA patients [6]. Nuclear
staining was observed for NASP (A), cytoplasmic staining was observed for RCAS1 (B) and
eIF5A (C), nuclear staining was observed for NBS1 (D). Magnification in all panels is X20.
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Immunohistochemical staining for MRE11, Her2, and p53 in tissue sections obtained from a
patient with serous high grade carcinoma. Immunohistochemical staining for RAD50 was
performed in tissue sections obtained from a patient with mixed epithelial carcinoma.
Although MRE11 and RAD50 were not previously identified as serological biomarkers,
IHC was performed to determine their protein expression level because of their biological
functions as stated earlier. Known prognostic markers Her2 and p53 were also included in
this study. Nuclear staining was observed for MRE11 (A) and RAD50 (B), membranous
staining was observed for Her2 (C), nuclear staining was observed for p53 (D).
Magnification in all panels is X20.
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Graphical representation of protein expression level obtained by IHC as the percent of cells
positively staining for each antigen biomarker. The protein expression of NASP (A),
RCAS1 (B), eIF5A (C) and NBS1 (D) in normal (healthy women), serous cystadenoma,
early and late stage serous OVCA, early and late stage non-serous OVCA is shown above.
The gray bar indicates the median value for each class of tissue sample.
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Graphical representation of protein expression level of biomarkers obtained by IHC as the
percent of cells positively staining for each antigen biomarker The protein expression of
MRE11 (A), RAD50 (B) and 2 known biomarkers Her2 (C), and p53 (D) in normal (healthy
women), serous cystadenoma, early and late stage serous OVCA, early and late stage non-
serous OVCA is shown above. The gray bar indicates the median value for each class of
tissue sample.
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Graphical representation of protein expression level of serological biomarkers in Type I and
Type II OVCA obtained by IHC as the percent of cells positively staining for each antigen
biomarker. The protein expression of NASP (A), RCAS1 (B), eIF5A (C) and NBS1 (D) in
normal (healthy women), serous cystadenoma, Type I and Type II OVCA (see Materials and
Methods) is shown above. The gray bar indicates the median value for each class of tissue
sample.
Ali-Fehmi et al. Page 18














Graphical representation of protein expression level of other biomarkers in Type I and Type
II OVCA obtained by IHC as the percent of cells positively staining for each antigen
biomarker. The protein expression of MRE11 (A), RAD50 (B) and 2 known biomarkers
Her2 (C), and p53 (D) in normal (healthy women), serous cystadenoma, Type I and Type II
OVCA (see Materials and Methods) is shown above. The gray bar indicates the median
value for each class of tissue sample.
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Age [Median (Interquartile Range)] 57 (49, 67) 52 (42, 66) 49 (44, 60)
Range 27–87 31–89 41–67
Cohort II
Age [Median (Interquartile Range)] 58 (48, 69) - - - - - -
Range 20–89
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